{"entity":{"id":"nct05969041","kind":"trial","name":"Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors","aka":[],"tldr":"This study tests TROP-2-directed treatment; the registry reports that it is recruiting.","summary":"The registry lists NCT05969041 as recruiting, last updated 2024-01-18. Enrolment is 48 planned participants, an estimate. Interventions: MT-302 (A). Primary measures include To evaluate the safety and tolerability of MT-302 through incidence of Adverse Events; To establish the maximum tolerated dose (MTD). No results are posted in the registry; this does not exclude separate publications.","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT05969041","url":"https://clinicaltrials.gov/study/NCT05969041"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["trop2"],"drugs":["mt-302"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05969041","phase":"1","setting":"MYE Symphony: A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors","sponsor":"Myeloid Therapeutics","started":"2023-08-02","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05969041/","neighbours":{"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"mt-302","kind":"drug","name":"MT-302","route":"/drugs/mt-302/"}]}}